JP2007521272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521272A5 JP2007521272A5 JP2006517373A JP2006517373A JP2007521272A5 JP 2007521272 A5 JP2007521272 A5 JP 2007521272A5 JP 2006517373 A JP2006517373 A JP 2006517373A JP 2006517373 A JP2006517373 A JP 2006517373A JP 2007521272 A5 JP2007521272 A5 JP 2007521272A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- aminobenzoyl
- aza
- spiro
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, fluoro, methoxy Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021036 Hyponatraemia Diseases 0.000 claims 2
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 2
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 *c1cc(C(Nc2ccc(C(N(CC3)c4ccccc4C[C@@]3(CC3)C=C3C(O)=O)=O)c(*)c2*)=O)c(*)cc1 Chemical compound *c1cc(C(Nc2ccc(C(N(CC3)c4ccccc4C[C@@]3(CC3)C=C3C(O)=O)=O)c(*)c2*)=O)c(*)cc1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47937803P | 2003-06-17 | 2003-06-17 | |
| US60/479,378 | 2003-06-17 | ||
| PCT/US2004/019460 WO2005037795A2 (en) | 2003-06-17 | 2004-06-16 | Substituted spirobenzazepines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007521272A JP2007521272A (ja) | 2007-08-02 |
| JP2007521272A5 true JP2007521272A5 (https=) | 2007-09-13 |
| JP5252614B2 JP5252614B2 (ja) | 2013-07-31 |
Family
ID=34465052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517373A Expired - Fee Related JP5252614B2 (ja) | 2003-06-17 | 2004-06-16 | 置換スピロベンズアゼピン |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20040266752A1 (https=) |
| EP (1) | EP1633719B1 (https=) |
| JP (1) | JP5252614B2 (https=) |
| KR (1) | KR101086246B1 (https=) |
| CN (1) | CN100467454C (https=) |
| AR (1) | AR044782A1 (https=) |
| AT (1) | ATE444953T1 (https=) |
| AU (1) | AU2004281257C1 (https=) |
| BR (1) | BRPI0411598A (https=) |
| CA (1) | CA2529649C (https=) |
| CL (1) | CL2004001507A1 (https=) |
| CR (1) | CR8168A (https=) |
| CY (1) | CY1109585T1 (https=) |
| DE (1) | DE602004023501D1 (https=) |
| DK (1) | DK1633719T3 (https=) |
| EA (1) | EA011089B1 (https=) |
| ES (1) | ES2332724T3 (https=) |
| HR (2) | HRP20090606T1 (https=) |
| IL (1) | IL172630A (https=) |
| ME (1) | ME00320B (https=) |
| NO (1) | NO20060247L (https=) |
| NZ (1) | NZ544180A (https=) |
| PL (1) | PL1633719T3 (https=) |
| PT (1) | PT1633719E (https=) |
| RS (1) | RS20050930A (https=) |
| SI (1) | SI1633719T1 (https=) |
| TW (1) | TWI354555B (https=) |
| UA (1) | UA82236C2 (https=) |
| WO (1) | WO2005037795A2 (https=) |
| ZA (1) | ZA200600430B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007516177A (ja) * | 2003-06-17 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法 |
| CA2637838A1 (en) * | 2006-01-20 | 2007-07-26 | Janssen Pharmaceutica N.V. | Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid |
| PT2078022E (pt) * | 2006-09-22 | 2012-01-11 | Janssen Pharmaceutica Nv | Espiro benzazepinas utilizadas como antagonistas de vasopressina |
| JP2010504352A (ja) * | 2006-09-22 | 2010-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
| AR066834A1 (es) * | 2007-06-06 | 2009-09-16 | Janssen Pharmaceutica Nv | Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central. |
| CA2705097A1 (en) * | 2007-11-07 | 2009-05-14 | Janssen Pharmaceutica N.V. | Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists |
| WO2014062888A1 (en) | 2012-10-18 | 2014-04-24 | University Of South Florida | Compositions and methods for treating stroke |
| JP5968466B2 (ja) | 2012-12-26 | 2016-08-10 | 株式会社三和化学研究所 | 新規ベンゾアゼピン誘導体及びその医薬用途 |
| TW202246273A (zh) * | 2021-03-05 | 2022-12-01 | 大陸商上海濟煜醫藥科技有限公司 | 新型苯并氮雜卓并環衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| US5985869A (en) * | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| DK0450097T3 (da) | 1989-10-20 | 1996-05-20 | Otsuka Pharma Co Ltd | Benzoheterocykliske forbindelser |
| US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5663431A (en) * | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| WO1994007496A1 (en) * | 1992-10-07 | 1994-04-14 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| WO1995028930A1 (en) * | 1994-04-22 | 1995-11-02 | Pentech Pharmaceuticals, Inc. | Dosage forms and method for ameliorating male erectile dysfunction |
| US5753648A (en) * | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| JP3282494B2 (ja) * | 1995-05-16 | 2002-05-13 | 富士ゼロックス株式会社 | 画像定着装置 |
| US5753715A (en) | 1995-06-02 | 1998-05-19 | Ortho Pharmaceutical Corporation | 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents |
| US5726723A (en) * | 1996-01-31 | 1998-03-10 | Technology Research International Corporation | Sub-twisted nematic liquid crystal display |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| US7001898B2 (en) * | 2000-07-05 | 2006-02-21 | Ortho-Mcneil Pharmaceutical, Inc. | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| JP2007516177A (ja) * | 2003-06-17 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法 |
-
2004
- 2004-06-16 DE DE602004023501T patent/DE602004023501D1/de not_active Expired - Lifetime
- 2004-06-16 JP JP2006517373A patent/JP5252614B2/ja not_active Expired - Fee Related
- 2004-06-16 HR HR20090606T patent/HRP20090606T1/hr unknown
- 2004-06-16 ES ES04809449T patent/ES2332724T3/es not_active Expired - Lifetime
- 2004-06-16 SI SI200431304T patent/SI1633719T1/sl unknown
- 2004-06-16 US US10/869,746 patent/US20040266752A1/en not_active Abandoned
- 2004-06-16 UA UAA200512207A patent/UA82236C2/uk unknown
- 2004-06-16 ME MEP-2008-491A patent/ME00320B/me unknown
- 2004-06-16 WO PCT/US2004/019460 patent/WO2005037795A2/en not_active Ceased
- 2004-06-16 CN CNB2004800231176A patent/CN100467454C/zh not_active Expired - Fee Related
- 2004-06-16 EA EA200501831A patent/EA011089B1/ru not_active IP Right Cessation
- 2004-06-16 AT AT04809449T patent/ATE444953T1/de active
- 2004-06-16 DK DK04809449T patent/DK1633719T3/da active
- 2004-06-16 NZ NZ544180A patent/NZ544180A/en not_active IP Right Cessation
- 2004-06-16 PT PT04809449T patent/PT1633719E/pt unknown
- 2004-06-16 CA CA2529649A patent/CA2529649C/en not_active Expired - Fee Related
- 2004-06-16 BR BRPI0411598-8A patent/BRPI0411598A/pt not_active Application Discontinuation
- 2004-06-16 EP EP04809449A patent/EP1633719B1/en not_active Expired - Lifetime
- 2004-06-16 KR KR1020057024157A patent/KR101086246B1/ko not_active Expired - Fee Related
- 2004-06-16 AU AU2004281257A patent/AU2004281257C1/en not_active Ceased
- 2004-06-16 RS YUP-2005/0930A patent/RS20050930A/sr unknown
- 2004-06-16 AR ARP040102087A patent/AR044782A1/es not_active Application Discontinuation
- 2004-06-16 PL PL04809449T patent/PL1633719T3/pl unknown
- 2004-06-16 TW TW093117253A patent/TWI354555B/zh not_active IP Right Cessation
- 2004-06-16 HR HR20051006A patent/HRP20051006A2/hr not_active Application Discontinuation
- 2004-06-17 CL CL200401507A patent/CL2004001507A1/es unknown
-
2005
- 2005-12-15 IL IL172630A patent/IL172630A/en active IP Right Grant
-
2006
- 2006-01-02 CR CR8168A patent/CR8168A/es not_active Application Discontinuation
- 2006-01-16 ZA ZA200600430A patent/ZA200600430B/xx unknown
- 2006-01-17 NO NO20060247A patent/NO20060247L/no not_active Application Discontinuation
-
2007
- 2007-04-13 US US11/735,149 patent/US7687494B2/en not_active Expired - Fee Related
-
2009
- 2009-12-11 CY CY20091101295T patent/CY1109585T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183410A5 (https=) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| JP2007502287A5 (https=) | ||
| JP2004518763A5 (https=) | ||
| JP2006526031A5 (https=) | ||
| WO2008044656A1 (fr) | Dérivé d'imidazolidinone | |
| JP2005529840A (ja) | Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療 | |
| JP2010504351A5 (https=) | ||
| JP4040089B2 (ja) | ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体 | |
| JP6452731B2 (ja) | アミノカルボニルカルバメート化合物 | |
| JP2009538873A5 (https=) | ||
| JP2005525337A5 (https=) | ||
| EP2308828A3 (en) | CaSR antagonist | |
| JP2007521272A5 (https=) | ||
| JP2005511697A5 (https=) | ||
| EP3126361A1 (en) | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| JP2004527492A5 (https=) | ||
| US5840979A (en) | Aliphatic propargylamines as cellular rescue agents | |
| CN101460484A (zh) | 6-甲氧基-8-[4-(1-(5-氟)-喹啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉盐酸盐 | |
| JP2005511559A5 (https=) | ||
| WO2007074078A3 (en) | Aryl-isoxazol-4-yl-imidazole derivatives | |
| WO2010098286A1 (ja) | ミネラルコルチコイド受容体拮抗薬を含有する医薬 | |
| CA2529649A1 (en) | Substituted spirobenzazepines |